
Merck & Co. MRK
Annual report 2025
added 02-24-2026
Country |
|
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NYSESPB |
Shares |
2.5 B |
Market Cap[1] |
$ 304 B |
EBITDA (LTM) |
$ 2.86 B |
P/E (LTM) |
16.71 |
P/S (LTM) |
4.7 |
EPS (LTM) |
7.34 |
Merck & Co., Inc. is a global pharmaceutical company that specializes in the development, manufacturing, and distribution of innovative medicines, vaccines, and animal health products. Founded in 1891, Merck has grown to become one of the largest pharmaceutical companies in the world, with operations in over 140 countries.
The company's mission is to improve the health and well-being of people and animals around the world. Merck is committed to discovering new treatments and cures for some of the most challenging diseases, including cancer, Alzheimer's disease, and HIV/AIDS. The company has a strong pipeline of products in development, with a focus on immunotherapy and oncology.
Merck is also a leader in the development and distribution of vaccines. The company has played a key role in the fight against infectious diseases such as measles, mumps, rubella, and HPV. Merck's vaccines have saved countless lives around the world and continue to be an important tool in preventing disease outbreaks.
In addition to its pharmaceutical and vaccine business, Merck also has a thriving animal health division. The company develops and manufactures products for livestock, pets, and wildlife. Merck's animal health products are used to prevent and treat diseases in animals, improving their health and welfare.
Merck is committed to operating responsibly and sustainably. The company has set ambitious goals to reduce its environmental impact, improve the health and safety of its employees, and support the communities where it operates. Merck has been recognized for its sustainability efforts, including being named to the Dow Jones Sustainability Index for the past 16 years.
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market | ||
|
Adverum Biotechnologies
ADVM
|
- | - | $ 86.2 M | Nasdaq Global Market | ||
|
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | ||
|
Nanobiotix S.A.
NBTX
|
$ 30.34 | -0.82 % | $ 286 B | Nasdaq Global Select Market | ||
|
Allakos
ALLK
|
- | - | $ 28.6 M | Nasdaq Global Select Market,SPB | ||
|
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market | ||
|
Akebia Therapeutics
AKBA
|
$ 1.4 | -0.71 % | $ 360 M | Nasdaq Global Market | ||
|
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | ||
|
Applied Molecular Transport
AMTI
|
- | - | $ 10.1 M | Nasdaq Global Select Market,SPB | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | ||
|
Genfit SA
GNFT
|
- | 2.54 % | $ 160 B | Nasdaq Global Select Market | ||
|
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market | ||
|
Applied Therapeutics
APLT
|
- | - | $ 8.42 M | Nasdaq Global Market,SPB | ||
|
Aravive
ARAV
|
- | -13.39 % | $ 1.45 M | Nasdaq Global Select Market | ||
|
BioNTech SE
BNTX
|
$ 95.5 | 3.83 % | $ 27.2 B | Nasdaq Global Select Market | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | ||
|
Can-Fite BioPharma Ltd.
CANF
|
$ 2.92 | -0.34 % | $ 6.35 B | NYSE American | ||
|
Aytu BioScience
AYTU
|
$ 2.55 | -0.78 % | $ 16 M | Nasdaq Capital Market | ||
|
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market | ||
|
AstraZeneca PLC
AZN
|
- | - | $ 96.9 B | Nasdaq Global Select Market | ||
|
AVROBIO
AVRO
|
- | 1083.1 % | $ 745 M | Nasdaq Global Select Market | ||
|
Advaxis
ADXS
|
- | -9.65 % | $ 45.9 M | Nasdaq Capital Market | ||
|
Amphastar Pharmaceuticals
AMPH
|
$ 20.37 | -2.4 % | $ 952 M | Nasdaq Global Select Market | ||
|
Brainstorm Cell Therapeutics
BCLI
|
- | -2.5 % | $ 5.88 M | Nasdaq Capital Market | ||
|
Aquestive Therapeutics
AQST
|
$ 4.08 | -2.16 % | $ 436 M | Nasdaq Global Market | ||
|
Ayala Pharmaceuticals
AYLA
|
- | - | $ 7.46 M | Nasdaq Global Market | ||
|
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX | ||
|
Arcutis Biotherapeutics
ARQT
|
$ 24.21 | -1.47 % | $ 3.08 B | Nasdaq Global Select Market,SPB | ||
|
BeiGene, Ltd.
BGNE
|
- | 0.49 % | $ 251 B | Nasdaq Global Select Market | ||
|
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market | ||
|
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | ||
|
Celldex Therapeutics
CLDX
|
$ 32.24 | -4.1 % | $ 2.14 B | Nasdaq Global Select Market | ||
|
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | ||
|
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | ||
|
CymaBay Therapeutics
CBAY
|
- | - | $ 3.45 B | Nasdaq Global Select Market | ||
|
AIkido Pharma
AIKI
|
- | 1.93 % | $ 17.4 M | Nasdaq Capital Market | ||
|
Cabaletta Bio
CABA
|
$ 3.13 | -1.26 % | $ 315 M | Nasdaq Global Select Market | ||
|
Codiak BioSciences
CDAK
|
- | -55.98 % | $ 2.15 M | Nasdaq Global Market | ||
|
Aptose Biosciences
APTO
|
- | -45.71 % | $ 1.2 M | Nasdaq Capital Market | ||
|
Avid Bioservices
CDMO
|
- | - | $ 789 M | Nasdaq Capital Market | ||
|
Cidara Therapeutics
CDTX
|
- | - | $ 1.41 B | Nasdaq Global Market | ||
|
InflaRx N.V.
IFRX
|
$ 1.0 | -2.91 % | $ 152 M | Nasdaq Global Select Market | ||
|
Immutep Limited
IMMP
|
$ 0.31 | -2.52 % | $ 1.08 B | Nasdaq Global Market | ||
|
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | ||
|
Checkpoint Therapeutics
CKPT
|
- | - | $ 169 M | Nasdaq Capital Market | ||
|
CureVac N.V.
CVAC
|
- | - | $ 867 M | Nasdaq Global Market | ||
|
Concert Pharmaceuticals
CNCE
|
- | - | $ 401 M | Nasdaq Global Market | ||
|
Akari Therapeutics, Plc
AKTX
|
$ 3.83 | -2.3 % | $ 258 B | Nasdaq Capital Market | ||
|
Akouos
AKUS
|
- | 0.23 % | $ 488 M | Nasdaq Global Select Market | ||
|
Celsion Corporation
CLSN
|
- | -6.63 % | $ 13.9 M | Nasdaq Capital Market |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.